VBL Therapeutics to Report Third Quarter Financial Results on November 15

Rhea-AI Summary

VBL Therapeutics (Nasdaq: VBLT) announced it will release its third quarter financial results for the period ending September 30, 2021, on November 15, before market open. CEO Professor Dror Harats and CFO Sam Backenroth will host a conference call at 8:30 AM ET to discuss the results and provide a corporate update. VBL is focused on developing first-in-class therapeutics for challenging malignant solid tumors, with its lead candidate, ofranergene obadenovec, in a Phase 3 trial for platinum-resistant ovarian cancer.

TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release third quarter financial results for the period ended September 30, 2021 on Monday, November 15 before market open. Professor Dror Harats, M.D, Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update.

Conference Call:

Monday, November 15, 2021 at 8:30am ET

Conference ID: 10017250

US: 855-327-6837

Israel Local: 1-809-458-327

International: 631-891-4304

Webcast: https://edge.media-server.com/mmc/p/3bwajjar

About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications. VBL’s novel VTS™ gene-targeting platform and antibody-based monocyte targeting technology enable the creation of a pipeline of programs designed to harness the body’s innate biological processes to provide unique solutions for significant unmet medical needs. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111; 'ofra-vec'), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent in development to treat a wide range of solid tumors. VB-111 is currently being studied in a Phase 3 registration-enabling trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL Therapeutics, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.

CONTACT:
Catherine Day
+1-917-763-2709
Catherine@newdaybioconsulting.com

Erez Feige, VP Business Operations
IR@vblrx.com 

FAQ

When will VBL Therapeutics release its third quarter financial results?

VBL Therapeutics will release its third quarter financial results on November 15, 2021, before market open.

What is the conference call for VBL Therapeutics about?

The conference call for VBL Therapeutics will discuss the third quarter financial results and provide a corporate update, hosted by CEO Professor Dror Harats and CFO Sam Backenroth.

What is VBL Therapeutics' lead product candidate?

VBL Therapeutics' lead product candidate is ofranergene obadenovec (VB-111), which is in development for treating platinum-resistant ovarian cancer.

What is the conference call date and time for VBL Therapeutics?

The conference call for VBL Therapeutics is scheduled for November 15, 2021, at 8:30 AM ET.